Opthea Appoints Parisa Zamiri And Tom Reilly Respectively As Chief Medical Officer And Chief Financial Officer, As The Company Continues To Prepare For The Sozinibercept Phase 3 Topline Data Readouts Of COAST Anticipated In Early Q2 Calendar Year 2025 And ShORe In Mid Calendar Year 2025
Portfolio Pulse from Benzinga Newsdesk
Opthea has appointed Parisa Zamiri as Chief Medical Officer and Tom Reilly as Chief Financial Officer. The company is preparing for the Phase 3 data readouts of its Sozinibercept trials, COAST and ShORe, expected in 2025.
October 08, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Opthea has strengthened its leadership team with the appointments of Parisa Zamiri as CMO and Tom Reilly as CFO. This move is part of the company's preparation for the Phase 3 data readouts of its Sozinibercept trials, COAST and ShORe, expected in 2025.
The appointment of new executives in key roles suggests a strategic focus on upcoming clinical trial milestones. This could positively impact investor sentiment as the company prepares for significant data readouts in 2025.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90